Emerging evidence suggests that DOACs are likely to replace low molecular weight heparin as the standard of care for cancer-related thrombosis, with the possible exception of patients with GI cancer, an expert says. Speaking at Blood 2019, Professor John Eikelboom from McMaster University in Canada, told delegates that venous thromboembolism was a huge problem in ...
DOACs could become standard of care in cancer related VTE: expert
By Nicola Garrett
29 Oct 2019